9 hasil
FIELD OF THE INVENTION
This invention relates to analgesia. More particularly, this invention relates to a treatment of animals and humans by the administering of a substance that inhibits and/or delays the inherent breakdown of a class of naturally occurring analgesics that are created and exist
BACKGROUND
1. Technical Field
This document relates to methods and materials involved in using morphine, morphine precursors (e.g., reticuline), morphine-6.beta.-glucuronide, and inhibitors of morphine synthesis or activity to treat mammals.
2. Background Information
Many people suffer from
BACKGROUND
1. Technical Field
This document relates to methods and materials involved in using morphine, morphine precursors (e.g., reticuline), morphine-6.beta.-glucuronide, and inhibitors of morphine synthesis or activity to treat mammals.
2. Background Information
Many people suffer from
BACKGROUND
1. Technical Field
This document relates to methods and materials involved in using morphine, morphine precursors (e.g., reticuline), morphine-6.beta.-glucuronide, and inhibitors of morphine synthesis or activity to treat mammals.
2. Background Information
Many people suffer from
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an .omega.-(methanesulfonyl)alkenylnitrile compound, or its pharmaceutically acceptable salts. The present invention also relates to methods of using the compound
DESCRIPTION OF THE INVENTION
The present invention relates to modified amino acid amides of general formula ##STR2##
the tautomers, the diastereomers, the enantiomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or
BACKGROUND OF THE INVENTION
This invention relates to methods and compositions for treating pain in humans using a combination of the kappa-opioid nalbuphine, in a relatively low dosage, with a low dosage of an opioid antagonist selected from naloxone, naltrexone, and nalmefene.
Nalbuphine is a
PRIORITY TO RELATED APPLICATIONS
This application claims the benefit of European Application No. 05101324.1, filed Feb. 22, 2005, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Substance P is a naturally occurring undecapeptide belonging to the tachykinin
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Phase Entry of International Application No. PCT/EP2013/072203, filed on Oct. 23, 2013, which claims priority to French Patent Application Serial No. 1260097, filed on Oct. 23, 2012, both of which are incorporated by reference